Literature DB >> 7997079

Flucloxacillin-associated hepatic injury.

G H Koek1, B H Stricker, A P Blok, S W Schalm, V J Desmet.   

Abstract

Eleven cases of hepatic injury attributed to the intake of flucloxacillin were reported to the Netherlands Center for Monitoring of Adverse Reactions to Drugs between 1982 and 1992. They concerned four men and seven women, with a mean age of 57 years, treated for 2-28 days with an oral dose varying from 1500-4000 mg per day. Symptoms mostly appeared 10 to 30 days after starting treatment with flucloxacillin. Biochemically, the pattern was compatible with cholestatic hepatitis in seven cases, with a mixed cholestatic-hepatocellular type of injury in one case, a hepatocellular pattern in two cases, and mild liver enzyme elevations in one patient. Two patients died, one due to fatal bleeding from the liver after biopsy, and the second patient to a combination of hepatic and cardiac failure. The other patients recovered, on average 72 days after peaking of serum aminotransferase values. Histology in seven cases showed cholestatic hepatitis in five, with cholangitis or cholangiolitis in four of these patients. In the other two patients, there was centrilobular cholestasis with extensive bridging fibrosis and portal-central bridging necrosis, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7997079     DOI: 10.1111/j.1600-0676.1994.tb00079.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  6 in total

1.  Erythromycin-induced primary biliary cirrhosis.

Authors:  D A Lazarczyk; M C Duffy
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

2.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Severe cholestatic hepatitis following cloxacillin treatment.

Authors:  S Goland; S D Malnick; R Gratz; E Feldberg; D Geltner; Z M Sthoeger
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

4.  [Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].

Authors:  U Hartmann; S Schmitt; M Reuss-Borst
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 5.  Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Authors:  Sanja Dragovic; Nico P E Vermeulen; Helga H Gerets; Philip G Hewitt; Magnus Ingelman-Sundberg; B Kevin Park; Satu Juhila; Jan Snoeys; Richard J Weaver
Journal:  Arch Toxicol       Date:  2016-09-22       Impact factor: 5.153

6.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Authors:  Stefan J Dekker; Floor Dohmen; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.